

## ISPOR Lebanon Chapter

### Lebanese Society of PharmacoEconomics and Outcome Research

#### **Importance of PharmacoEconomics and Data Registry in Lebanon**

(Metropolitan- Sin El Fil/ November 25-26, 2016)

#### **I. This was a Two-Day Educational Program:**

##### **Learning Objectives:**

Day One of workshop (PE Module One): **PharmacoEconomics: Principles, Methods and Applications**. By the end of module one, you will be able to:

- State the role of PE in medical decision making
- Discuss the challenges of PE and current health economic situation
- Define type of costs and factors relevant to PE analysis
- Differentiate between types of PE models
- Apply stepwise approach to evaluate PE analysis
- Transferability of Model-Based Economic Evaluations

Day Two of workshop: **The Importance of Data Registry in HealthCare Systems**. By the end of this workshop, you will be able to:

- Identify the needs of data registry in Lebanon
- Learn the importance of Local HEOR data
- Be familiar with the benefit and utilization of building a data registry
- Discuss how to establish a data Registry
- Budget Impact Analysis Tool

**Accreditation:** This live activity is sponsored by ISPOR Lebanon Chapter. The Lebanese Order of Pharmacists designates this live educational activity for a maximum of **5 CE credit hours**.

##### **Organizing Committee:**

Board members of ISPOR Lebanon Chapter (LSPOR):

- Ghassan Hamadeh, MD, CPE – President
- Mirna Metni, Pharm.D. – President Elect
- Soumana Chamoun Nasser, Pharm.D. – Secretary & Activity Director
- Marie Therese Estephan Sawaya, MD - Treasurer
- Maher Hassoun, M.S. – Director of Communications
- Rita Karam, Pharm.D, PhD. – Board Member

- Myriam Watfa, Pharm.D. – Executive staff

## **II. Work accomplished:**

### *1. Day One*

Dr. Hamadeh opened the session by welcoming the audience. He introduced LSPOR's mission and vision and explained the importance of having this 4 course module.

Dr. Omar Dabbous then presented the importance of PE: Challenges and current health situation. The session was specifically designed for individuals working in the pharmaceutical industry, academia, and government agencies, who are not health economists but who need to understand the healthcare challenges and PE concepts to help facilitate conversations.

Dr. Salim Adib presented the second topic on Health Information Systems and PE in Lebanon: what we have and what we need. He explained the importance of having a "Health Information Systems (HIS) that should cover three categories of data: disease-related data such as disease incidence or prevalence of risk factors; utilization data such as number of MD visits, volume of drug use. While these categories of data may be obtained through channels working in separate silos, a central entity should exist where these data are compiled, analyzed and transformed into information useful for monitoring and evaluation purposes. He also emphasized the leadership role of the government, to ensure that the credible and sustainable architecture of HIS in Lebanon.

After the coffee break, the two board members Dr. Soumana Nasser and Mr. Maher Hassoun presented the PE principles, steps to PE evaluation, PE models and relevant cost definitions and factors.

Dr. Silvia Evers and Dr. Manuela Joore respectively talked over video conference about the steps in assessing the transferability of foreign CEA studies and transferability of Model-Based Economic Evaluations. Dr. Evers defined the term "transferability", its limitations, its diagnosis and ISPOR's task force. Dr. Joore discussed the steps of transferability of Model-Based Cost Effectiveness Analysis Positive.

The 1<sup>st</sup> day of the workshop ended with the case study of TRASTUZUMAB ® for the adjuvant treatment of HER-2 conducted by Dr. Joore and Dr. Evers and moderated by Dr. Mirna Metni followed by an open panel discussion.

### *2. Day two*

The workshop was animated by panel discussions over several subjects:

- Identify the Needs of Data Registry in Lebanon

- PharmacoEconomics: from Theory to Practice
- Registry Execution – Team, Governance and Oversight Plan

In addition to that, Dr. Dabbous talked about building a registry and the importance of HEOR Data. He also shared his knowledge with Dr. Fadia Elias and Dr. Georges Saadeh on Registry Outcome: Benefit and Utilization / Snapshot on Existing Registry Bodies.

Dr. Russel Becker concluded the educational workshop with an overview on Budget Impact Analysis Tool.

### *3- Closing session:*

A General Assembly meeting with LSPOR members was held at the end of the second day in order to discuss the next annual meeting that will take place on the 25<sup>th</sup> of February, 2017.

### **III. Workshop Evaluation Summary Results:**

The feedbacks were rather very positive based on evaluation forms filled by participants. In summary, several attendees found the program to be very interesting, rich in contents, delivered by expert in the field (who received high rating on the evaluation forms), included very interactive panel discussions allowing attendees to translate their vision into reality. All speakers received grades 3-4 over 4 score.

Suggestions raised includes: to provide workshops with interactive sessions to learn and apply steps in performing BIA, CEA, CUA, data transferability, as well as implementation of data registry. Involvement of public health sectors especially more members from the MOPH would be needed for future success.

#### ***Feedbacks as stated on the evaluation forms:***

1. It was productive and valuable. The panel discussion allowed us to translate our vision into reality. BIA tool utilization was very constructive and wholesome.
2. There is a need to have a more interactive workshop to be able to have practiced perspective.
3. We need some hands on experience workshop for cost-benefit, cost-utility.
4. It is an interesting workshop and I wish to elaborate more about transferability.
5. Enjoyable workshop that shed light on registration importance.
6. Thank you for your adequate program, it is very interesting subjects, but needs to give some examples not only theories and numbers, and we need to know the results of these studies on earth.
7. Very interesting topics! We suggest to discuss the role of Pharmacovigilance in Registries, how much the Pharmacovigilance center are involved to improve the cost effectiveness of the drugs, and to do not expend of money on an extra disease which are unexpected! Thank you for your hard work.
8. Practical examples / case studies / Have more of this workshop where applicable for example, health economics modelling hands on experience (mainly BIA, CEA, CUA).
9. Options for short courses and certifications, similar to what is usually done in ISPOR European and International meeting, to increase expertise in some areas.
  - Other Topics suggested: Biologics / Biosimilar
  - Resource allocation: how to make such decisions in health care

- Financing health care in rare/orphan diseases: current trends, challenges, and considerations for the future.
  - Pay for performance contracting, outcomes based models, risk sharing agreements.
10. As attending a workshop, we need more practical and case studies
  11. All topics were well illustrated, but the skype presentation was not efficient. I need to have more information and details about transferability.
  12. More subjects related to pharmacoeconomics and market access importance and applications.
  13. Very interesting workshop. Interested in BIA workshop
  14. Excellent 360 degree approach, built partnership with all stakeholders.
  15. Panel (more focus) (shorter) avoid repetition, time management
  16. In general it was good but each topic should be discussed by one workshop alone.
  17. It was good at the end. Dr. Russel was perfect and for future workshop I like to learn more concerning budget impact analysis tool.
  18. Very enriched workshop. More involvement from MOH authorities is needed for future success.
  19. MEDRES was not mentioned and Mrs ----- was not present. Future development in medical devices fields is needed since a phone application and medical devices are more and more contributing in the health sector.
  20. Next time focus on an interactive session for calculation of ICER for example.
  21. For next time, elaborate steps of implementation of a registry (commercial, academic ...)
  22. It is better to put action plan (implementation) and not only discussion and opinion related to the data registry in Lebanon since all stakeholders are available (MOPH, NSSF, Army, insurance, pharma companies ...)
  23. Workshop on a model of cost utility and steps to do the analysis.
  24. Very beneficial but the idea of transferability wasn't clearly demonstrated.
  25. It would be great if better time management is done to respect timeline. Classroom style with tables would be opportune for such workshop. Try to make the presentations more interactive.
  26. Interesting introduction to pharmacoeconomics, it was clear and important discussion.
  27. The Panel discussion is very interactive session. The discussions should be taken on a national level and we encourage you to be a plan, smart objectives and a timeline.
  28. I loved Dr. Saade's ppt, it's very informative, self-explanatory and full of figures (charts, histograms ...)
  29. The 2 days conference provide us that this research tract trains the providers of registry critically analyze the impact of outcomes to pharmaceutical products and services with the health care system and looks for the impact of data organization systems.